Variegate Porphyria

Variegate porphyria is another type of porphyria. It affects the liver and can cause both skin problems and nervous system issues. It's caused by a missing enzyme in the liver needed to make heme.

Condition

What people with Variegate Porphyria report

Every report comes from a Lived member, sent anonymously.

Have you tried Hemin for Variegate Porphyria?

NameHow it went

About Variegate Porphyria

What It Is

Variegate porphyria (VP) is a rare inherited condition in which the liver has trouble completing the last steps of making heme, an iron-containing molecule that many of the body's proteins depend on. One enzyme in that process, protoporphyrinogen oxidase, works at roughly half its usual level. When the liver is pushed to make more heme, substances from earlier in the process build up and spread through the body. Depending on which ones accumulate, the result can be skin damage from sunlight, attacks that affect the nervous system, or both. The name "variegate" refers to this mix of possible symptoms. Skin problems are the more frequent feature. Skin that gets sun becomes fragile, tears or blisters after minor bumps, and heals slowly, sometimes leaving scars, tiny white bumps (milia), darker or lighter patches, or extra hair growth. Acute attacks are less common but more serious. They usually start with severe abdominal pain, often with nausea, vomiting, constipation, a fast heart rate and raised blood pressure, and can progress to confusion, seizures or muscle weakness. Many people who carry the gene change never have symptoms, and symptoms are rare before puberty. VP belongs to the acute hepatic porphyrias, a small group that includes the more common acute intermittent porphyria. Its blisters look the same as those of porphyria cutanea tarda, a porphyria that affects only the skin, so telling the two apart matters: only VP carries the risk of acute attacks.

Causes & Risk Factors

VP is caused by a change (variant) in PPOX, the gene that holds the instructions for protoporphyrinogen oxidase. It follows an autosomal dominant pattern: one altered copy, from either parent, is enough, and each child of a person with the variant has a 50% chance of inheriting it. Very rarely, a child inherits a variant from both parents. That form starts in infancy or childhood and can affect development and cause sun sensitivity, though acute attacks are not a prominent part of it. Carrying the variant is not the same as being ill. Most carriers never have an attack, and attacks usually follow something that makes the liver produce more heme, which overwhelms the weakened enzyme. Known triggers include certain medicines (including some hormonal birth control, antibiotics, anesthetics and seizure medicines), progesterone in the second half of the menstrual cycle, fasting or cutting back sharply on calories or carbohydrates, alcohol, smoking, and the stress of an infection or other illness. Sometimes no trigger is found. Attacks are more common in women and mostly happen between puberty and menopause. Skin symptoms come from sunlight reacting with the porphyrins that have collected in the skin. VP is rare in most populations, roughly 1 in 100,000 people of European descent. It is far more common among white South Africans of Dutch (Afrikaner) ancestry, an estimated 1 to 3 per 1,000, because many descend from a single settler of the late 1600s who carried the same variant.

How It's Diagnosed

Neither the skin changes nor the attack symptoms are specific to VP, so diagnosis relies on laboratory testing. When an attack is suspected, the key test is a single urine sample measuring porphobilinogen (PBG) and aminolevulinic acid (ALA), the two substances that build up during attacks, adjusted for how concentrated the urine is. During an attack they are at least five times the upper limit of normal. In VP these levels can return to normal quickly after an attack, so testing while symptoms are present matters, and a normal result weeks later does not fully rule VP out. These tests are usually sent to specialized laboratories and can take one to two weeks, so treatment for a likely attack may start before results return. To identify VP specifically, laboratories measure porphyrins in blood plasma and stool. Plasma from people with active VP gives off a characteristic glow under a particular light (a fluorescence peak near 626 nanometers), and stool shows raised protoporphyrin. These findings separate VP from porphyria cutanea tarda and other porphyrias with similar blisters. A mildly raised urine porphyrin level on its own occurs in many other conditions and is a common cause of mistaken porphyria diagnoses. Genetic testing for a PPOX variant confirms the diagnosis once biochemical tests point to VP, and it can help when symptoms have been absent for a long time. Once the family's variant is known, parents, siblings and children can be tested for it reliably, so that carriers can learn to avoid triggers even if they have never had symptoms.

Treatment Options

No treatment corrects the underlying enzyme deficiency. Care focuses on avoiding attacks, treating them quickly when they happen, and protecting the skin. Prevention starts with triggers. People with VP, and carriers, are advised to avoid alcohol and smoking, not to fast or follow very low-calorie diets, and to check every new medicine, including anesthesia, against a porphyria drug-safety list with their clinician or pharmacist. Wearing a medical alert bracelet or carrying a card that names the condition helps in an emergency. An attack severe enough to need hospital care is treated by stopping any medicine that may have set it off, giving sugar (glucose) by vein or mouth, controlling pain and nausea with medicines known to be safe in porphyria, and correcting high blood pressure, a fast heart rate and low sodium. The main specific treatment is hemin (Panhematin in the US), a form of heme given by infusion into a vein, usually once a day for about four days. It signals the liver to slow production of the substances causing the attack, and symptoms usually begin to ease within two to three days. Timing matters: hemin helps prevent nerve damage but does not repair damage already done. If seizures occur, the medicines used to treat them are chosen carefully, because several common seizure medicines can make an attack worse. A small number of people have frequent attacks, often defined as four or more a year. For them, preventive options include givosiran (Givlaari), a monthly injection under the skin approved for adults that reduces the liver's production of the attack-causing substances. In its main trial it cut attacks by about 70% compared with placebo, but almost all participants had acute intermittent porphyria and only two had VP. It requires regular blood tests of liver and kidney function and is not recommended during pregnancy or when planning one. Regularly scheduled hemin infusions are another option, with trade-offs that include a long-term IV line, infection risk and iron buildup. Hormone treatment can help when attacks follow the menstrual cycle, with limited success, and liver transplant is reserved for rare cases that do not respond to anything else. Skin symptoms are managed mainly by protection from sunlight: hats, long sleeves and other covering clothing, and opaque sunscreens, since ordinary sunscreens may not block the light that causes damage. Iron supplements taken by mouth can flare the skin disease, so if iron is needed, clinicians may prefer giving it by vein.

What to Expect

The course of VP varies widely. Many carriers never have symptoms. Among people who do have acute attacks, most have only one or a few in their lifetime, often linked to an identifiable trigger, while a small minority have frequent attacks and may have ongoing pain or nerve symptoms between them. An attack typically lasts days to weeks, and recovery from severe weakness is generally slow. Skin symptoms tend to be long-lasting and can persist for months or years, and they may be less common in cooler, less sunny climates. Living with them usually means planning around sun exposure and protecting the hands and other uncovered skin from scrapes. People who avoid sunlight closely may have low vitamin D, which is worth checking. VP also carries long-term risks that call for monitoring even when someone feels well. Acute hepatic porphyrias are linked with a higher risk of liver cancer, chronic kidney disease, high blood pressure and nerve damage. Most of the liver cancer data come from acute intermittent porphyria, and the size of the risk in VP is not known. Experts advise yearly checks for liver disease, yearly kidney tests for people on treatment, and, from age 50, a liver ultrasound every six months. Because VP is uncommon, care is often coordinated with a porphyria specialist, and genetic counseling can help families understand who should be tested.

When to Seek Help

Arrange an evaluation if sun-exposed skin repeatedly blisters, tears easily or scars, or if you have had episodes of severe, unexplained abdominal pain, especially with a family history of porphyria. If a relative has been diagnosed with VP, ask about genetic testing. Before surgery or any new prescription, remind the clinician that you have VP. If you have VP or carry the variant and develop the kind of abdominal pain, nausea or vomiting that could signal an attack, contact your care team right away rather than waiting it out, since early treatment helps prevent nerve damage. Go to an emergency department if the pain is severe or not controlled at home, vomiting will not stop, or you notice muscle weakness, a seizure, confusion or hallucinations. Call 911 for trouble breathing, which can mean weakness has reached the breathing muscles. Tell the staff that you have VP so they can avoid unsafe medicines.

Questions to Ask Your Doctor

  1. 1.Which tests confirmed my diagnosis, and should my urine be tested the next time I have symptoms of an attack?
  2. 2.How can I check whether a new medicine, anesthetic or supplement is safe for me with VP?
  3. 3.What should I do, and where should I go, if I think an attack is starting?
  4. 4.Which family members should be offered genetic testing, and what would a positive result mean for them?
  5. 5.What long-term monitoring of my liver, kidneys and blood pressure do I need, and when should it start?

Last reviewed • Oct 2026

Educational content, not medical advice.